Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Inc. (MIST) priced its initial public offering on May 9, 2019 at $15.00 per share, within its $14.00–$16.00 range, raising $82.5M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $354.7M. Jefferies was lead-left underwriter, joined by TD Cowen and Oppenheimer. Cooley and Osler advised the company and WilmerHale and McCarthy Tétrault advised the underwriters.

Milestone Pharmaceuticals Inc. is a Phase 3 clinical-stage biopharmaceutical company developing etripamil for cardiovascular indications. Etripamil is a short-acting calcium channel blocker given as a nasal spray by patients to end episodes of paroxysmal supraventricular tachycardia, a rapid heart rate condition.

Status

IPO

Ticker

MIST

Exchange

Nasdaq Global Select

Priced

May 9, 2019

IPO price

$15.00

Price range

$14.00–$16.00

Raised

$82.5M

Market cap at IPO price

$354.7M

First filed

Apr 12, 2019

Underwriters

Jefferies, TD Cowen and Oppenheimer

Company counsel

Cooley and Osler

Underwriters' counsel

WilmerHale and McCarthy Tétrault

Sector

Biotech & pharma

Country / state

Quebec, Canada

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.